Dimensional Fund Advisors LP Lowers Position in LENSAR, Inc. (NASDAQ:LNSR)

Dimensional Fund Advisors LP trimmed its stake in LENSAR, Inc. (NASDAQ:LNSR - Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 614,384 shares of the company's stock after selling 34,575 shares during the period. Dimensional Fund Advisors LP owned about 5.29% of LENSAR worth $5,492,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of LNSR. Geode Capital Management LLC lifted its position in shares of LENSAR by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company's stock worth $460,000 after purchasing an additional 3,423 shares during the period. Atria Investments Inc lifted its holdings in LENSAR by 28.2% in the fourth quarter. Atria Investments Inc now owns 26,055 shares of the company's stock valued at $233,000 after buying an additional 5,729 shares during the period. Essex Investment Management Co. LLC grew its holdings in LENSAR by 18.3% during the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company's stock worth $357,000 after acquiring an additional 6,184 shares during the period. Evernest Financial Advisors LLC acquired a new position in shares of LENSAR in the 4th quarter valued at about $174,000. Finally, Bailard Inc. acquired a new stake in LENSAR during the fourth quarter worth approximately $181,000. 40.15% of the stock is owned by institutional investors.

LENSAR Price Performance

Shares of LNSR stock traded down $0.01 on Friday, reaching $14.11. 57,272 shares of the company were exchanged, compared to its average volume of 75,523. The company has a 50-day moving average of $14.14 and a 200-day moving average of $10.68. The company has a market cap of $166.39 million, a price-to-earnings ratio of -9.66 and a beta of 0.56. LENSAR, Inc. has a one year low of $3.50 and a one year high of $17.31.

LENSAR (NASDAQ:LNSR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $11.53 million during the quarter, compared to the consensus estimate of $13.40 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. BTIG Research lowered LENSAR from a "strong-buy" rating to a "hold" rating in a research note on Monday, March 24th. Lake Street Capital reissued a "hold" rating and set a $15.00 target price (down from $16.00) on shares of LENSAR in a research note on Monday, March 24th.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.